Key result
Nitroglycerin-mediated dilatation was significantly lower in type 2 diabetic patients with microangiopathy (12.1% vs 15.7%) and macroangiopathy (10.3% vs 14.4%) compared to those without.
Why the study?
Are endothelial and vascular smooth muscle dysfunction associated with micro-/macroangiopathy and cardiovascular risk factors in type 2 diabetic patients?
Cross-Sectional (n=181)
No
Are endothelial and vascular smooth muscle dysfunction associated with micro-/macroangiopathy and cardiovascular risk factors in type 2 diabetic patients?
Absolute Event Rate: 12.1% vs 15.7%
p-value: p=0.001
In type 2 diabetic patients, vascular smooth muscle dysfunction (measured by NMD) is significantly associated with micro- and macroangiopathy and CKD progression, unlike endothelial dysfunction (measured by FMD).
Lower NMD associates with angiopathy and CKD in T2DM; leaves open whether smooth muscle dysfunction predicts events or warrants targeted intervention.
AIM: Atherosclerosis and arteriosclerosis are mainly caused by the dysfunction of arterial components, namely, vascular endothelial cells, smooth muscle cells, and the extracellular matrix. Endothelial dysfunction is well established as a predictive surrogate marker of cardiovascular events; however, little is known regarding the clinical implications of vascular smooth muscle dysfunction for cardiovascular disease and microangiopathy. In the present study, we aimed to clarify the association of arterial dysfunction with micro-/macroangiopathy and conventional cardiovascular risk factors in 181 type 2 diabetic patients (T2DM; age ± SD, 64 ± 10 years; duration of diabetes, 12 ± 10 years). METHODS: Flow-mediated dilatation (FMD) and nitroglycerin-mediated dilatation (NMD) were assessed to evaluate endothelial dysfunction and vascular smooth muscle dysfunction, respectively, by using a novel ultrasound device, UNEXEF18G (Unex Co. Ltd., Japan). RESULTS: The FMD and NMD were 6.4 ± 3.9% and 13.4 ± 6.6%, respectively. No significant differences in FMD were noted between T2DM with and without micro- or macroangiopathy; however, NMD in T2DM patients with micro- and macroangiopathy was significantly lower than that in T2DM patients without angiopathy. NMD decreased with the progression of chronic kidney disease (CKD) stage (p = 0.005), but not FMD (p = 0.071). On multiple regression analysis, significant independent contributors to FMD were age, smoking, systolic blood pressure, glycosylated hemoglobin, and serum total cholesterol, while those for NMD were age, systolic blood pressure, and waist circumference. CONCLUSION: The relationship of vascular complications and cardiovascular risk factors with NMD is different from that with FMD in type 2 diabetic patients.
No takes yet. Share an insight, caveat, or question.
Kawano et al. (2011) conducted a cross-sectional in Type 2 Diabetes Mellitus (n=181). Microangiopathy vs. No microangiopathy was evaluated on Nitroglycerin-mediated dilatation (NMD) (p=0.001). Nitroglycerin-mediated dilatation was significantly lower in type 2 diabetic patients with microangiopathy (12.1% vs 15.7%) and macroangiopathy (10.3% vs 14.4%) compared to those without.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: